0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
 
   Cambridge, UK and Indianapolis, US -- 24 January 2020: Acacia Pharma 
Group plc ("Acacia Pharma", the "Company", the "Group"), (EURONEXT: 
ACPH), a pharmaceutical company developing and commercialising hospital 
products for US and international markets, has been awarded BEL Small 
Company of the Year 2019 by Euronext Brussels at its annual New Year's 
Ceremony held in Brussels last night. 
 
   Mike Bolinder, CEO of Acacia Pharma, said: "We are delighted to be 
recognised with this award. In 2019, we have been finalizing our 
commercial strategy and infrastructure ahead of a number of key 
milestones expected during the first half of 2020. Regulatory decisions 
to approve two product candidates for marketing in the US, BARHEMSYS(R) 
and ByFavo(TM), are expected by 26 February and 5 April, respectively. 
These products address important unmet needs in the treatment and care 
of patients undergoing invasive medical procedures. Our US team is now 
preparing to commercialise these products, pending approval, and we are 
confident in the benefits and value they will bring to patients, 
healthcare providers and shareholders alike. We are looking forward to 
2020, which is expected to be an exciting and transformational year for 
Acacia Pharma." 
 
   The annual ceremony recognises the best performing companies in Belgium 
and is attended by 600 key stakeholders. BEL Small Company of the Year 
is awarded to a company that has demonstrated the highest relative 
increase in market capitalisation. The award was presented by the Prime 
Minister of Belgium, Sophie Wilmès. 
 
   Contacts 
 
   Acacia Pharma Group plc 
 
   Mike Bolinder, CEO 
 
   Christine Soden, CFO 
 
   +44 1223 919760 
 
   IR@acaciapharma.com 
 
   Citigate Dewe Rogerson (Financial PR) 
 
   Mark Swallow, Frazer Hall, David Dible 
 
   +44 20 7638 9571 
 
   acaciapharma@citigatedewerogerson.com 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialisation of new products designed to improve 
the treatment and care of patients undergoing invasive medical 
procedures or cancer therapy. The Group's pipeline includes near-market 
opportunities, which it plans to sell directly in the US through its own 
commercial operations, and in other territories through licensing and 
distribution agreements with selected partners. 
 
   The Group's pipeline includes: 
 
 
   -- BARHEMSYS(R) (intravenous amisulpride) for post-operative nausea & 
      vomiting (PONV) (NDA filed) 
 
   -- ByFavo(TM) (intravenous remimazolam), an ultra-short-acting and 
      reversible intravenous sedative/anaesthetic designed for use during 
      invasive medical procedures, such as during colonoscopy and bronchoscopy 
      (NDA filed), and 
 
   -- APD403 (intravenous and oral amisulpride) for chemotherapy induced nausea 
      & vomiting (CINV) (Phase 2) 
 
 
   Acacia Pharma is based in Cambridge, UK and Indianapolis, IN. The 
Company is listed on the Euronext Brussels exchange under the ISIN code 
GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com 
 
   Forward looking statement 
 
   This announcement includes forward-looking statements, which are based 
on current expectations and projections about future events. These 
statements may include, without limitation, any statements preceded by, 
followed by or including words such as "believe", "expect", "intend", 
"may", "plan", "will", "should", "could" and other words and terms of 
similar meaning or the negative thereof. Forward-looking statements may 
and often do differ materially from actual results. These 
forward-looking statements are subject to risks, uncertainties and 
assumptions about the Company and its subsidiaries and investments, 
including, among other things, the development of its business, trends 
in its operating industry, and future capital expenditures and 
acquisitions. By their nature, forward-looking statements involve risk 
and uncertainty because they relate to future events and circumstances. 
Any forward-looking statements reflect the Company's current view with 
respect to future events and are subject to risks relating to future 
events and other risks, uncertainties and assumptions relating to the 
Group's business, results of operations, financial position, prospectus, 
growth or strategies and the industry in which it operates. Save as 
required by law or applicable regulation, the Company and its affiliates 
expressly disclaim any obligation or undertaking to update, review or 
revise any forward-looking statement contained in this announcement 
whether as a result of new information, future developments or 
otherwise. Forward-looking statements speak only as of the date they are 
made. 
 
 
 
 
 
 

(END) Dow Jones Newswires

January 24, 2020 03:00 ET (08:00 GMT)

Grafico Azioni Acacia Pharma (LSE:0PNT)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Acacia Pharma (LSE:0PNT)
Storico
Da Apr 2023 a Apr 2024